Industry Research Reports

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

Global Printer Market 2014-2018

RELATED LINK:

Spectacle Lenses - Top 10 Global Markets Package

This market research report package offers a perspective on the actual market situation, trends and future outlook for spectacle lenses in the top 10 global countries. The studies provide essential market information for decision-makers including:

* Overall market value for spectacle lenses in the top 10 global countries

* Overall market volume for spectacle lenses in the top 10 global countries

* Market value and volume for spectacle lenses by product type

* Product prices

* Forecasts and future outlook of the market

* Country overview, macroeconomic indicators and indicators of doing business

These market studies answer to questions such as:

* What is the size of the spectacle lense markets in the top 10 global countries?

* How are the markets divided into different types of products? Which products are growing fast?

* How the markets have been developing? How does the future look like?

* What is the potential for the markets?

* How the indicators of doing business look like? For example, how easily the contracts are being enforced, or what is the inflation rate and how is it developing?

Product types discussed in the studies are:

* Spectacle lenses of glass

* Spectacle lenses of other materials

Countries included in the package:

Brazil, China, France, Germany, India, Italy, Japan, Russia, United Kingdom and United States

To order this report:

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

RELATED VIDEO:

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2014 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for January 2014 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database and primary and secondary research.

Scope

* Analysis of the market trends for the pharmaceutical industry in the global arena.

* Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

* Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

* Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

* Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

* Analysis of partnership and licensing deals based on clinical stage of development of products.

* Summary of the pharmaceutical deals globally in the six months.

* Information on the top deals happened in the pharmaceutical industry.

* Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

* League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

* Enhance your decision making capability in a more rapid and time sensitive manner.

* Find out the major deal performing segments for investments in your industry.

* Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

* Identify companies that are aggressively looking to raise capital in the market

* Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

* Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

* Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

* Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

* Identify growth segments and opportunities in each region within the industry.

* Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

To order this report:

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

Thursday, 17 April 2014

Offshore Drilling Industry in Middle East and Africa to 2016

Offshore Drilling Industry in Middle East and Africa to 2016 - Pre-Salt Potential in West Africa and Significant Gas Finds Off the East African Coast Driving Exploration Activity.

Summary

GBI Research, a leading business intelligence provider, has released its latest research, Offshore Drilling Industry in Middle East and Africa to 2016 - Pre-Salt Potential in West Africa and Significant Gas Finds Off the East African Coast Driving Exploration Activity. The study, produced by the companys Energy Research Group, provides an in-depth analysis of the offshore drilling market in the Middle East and Africa region and highlights the various concerns, shifting trends and major players in the region. The report provides forecasts for the offshore drilling industry in the Middle East and Africa region up to 2016. The report also provides segmented forecasts for the offshore drilling market in major countries in the Middle East and Africa region. In-depth analysis of key trends and challenges in the offshore drilling market in the region are also provided. An analysis of the competitive scenario, data on the offshore wells and drilling expenditure in the region are also provided for each market segment. This report has been compiled using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

* Overview and analysis of the offshore drilling industry in the Middle East and Africa

* Analysis of past market trends and forecasts to 2016

* Analysis and forecast for offshore wells drilled and offshore drilling expenditure

* Country-specific data analysis of Nigeria, Angola, Libya, Egypt, Qatar, UAE, Iran, and Saudi Arabia

* Analysis of opportunities and challenges in the emerging markets of the offshore drilling industry of Middle East and Africa

* Analysis of the competitive scenario for the offshore drilling industry in the Middle East and Africa

Reasons to buy

* Develop business strategies with the help of specific insights into the offshore drilling industry in Middle East and Africa.

* Identify opportunities and challenges in the offshore drilling industry in Middle East and Africa

* Increase future revenues and profitability with the help of insights on the future opportunities and critical success factors in the offshore drilling industry in the Middle East and Africa

* Benchmark operations and strategies against major players in the offshore drilling industry in Middle East and Africa

To order this report:

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

RELATED VIDEO:

Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The universe continues to grow despite the high risk and the wait to transform into a successful profitable Mature Biotech is long. 2012 saw new drugs approvals for unmet needs, first in class drugs for Anti-obesity, Myelofibrosis, cancers and better drug options for HCV, RA, MS, psoriasis, HCC, dyslipidemia etc. We expect approval of better drugs for bad bugs, targeted therapies for cancer, Alzheimers, antivirals and orphan diseases in the next five years.

Despite negative outcome of pivotal clinical trials or ruling by the FDA, no one (investors and large pharma/biotech companies) have given up on innovation which is reflected in the healthy cash position within the sector. Hope of resurrection will prevail in the next five years and successful commercialization of anti-obesity, dyslipidemia etc. could boost the Rs. sector. The expectation bar of investors for M&A is on the rise and with several Rs. companies accepting the challenge of marketing drugs on their own. Coming years will witness a mix of both- acquisitions as well as entering the Mature Biotech club. The race in innovations is killing newly launched novel drugs (ex. INCIVEK protease inhibitor for HCV) and patents do not offer protection from competition by better drugs in development. Diversified strategies will be essential both for the small and big players to mitigate these challenges as the life cycle of new drugs may be shorter than before in some therapy areas.

The New Avatars of Microbes is a growing threat world wide and we expect GAINS for companies focused in the anti-infective therapy class. Pill vs. Prick- is gaining popularity as new oral options are entering the market for RA, Psoriasis, MS etc. Pricing and experience of patients and physicians will drive compliance and define market opportunity of these drugs. Orphan disease focus will continue to remain attractive and success of Eteplirsen (PhII, Sarepta) for the treatment of Duchenne muscular dystrophy (DMD) and other antisense, RNAi drugs in the pipeline could see the final maturing of oligonucleotide based drug therapies.

Global Biopharmaceutical Outlook 2013 of the Rising Stars sector released by MP Advisors provides an in depth analyses of biotech companies and their drug pipeline amidst competition and dynamic regulatory environment. The report discusses the competitive landscape of the targeted therapy areas and the innovative strategy each company is deploying to surmount challenges and remain attractive for acquisitions, partnerships or march toward profitability. Sum of parts valuations of drugs in the pipeline are included after factoring clinical development risks and competition. Risk reward analyses of important upcoming milestones of the companies are included which should help fund managers as well as pharma company management to make critical decisions.

The detailed 109 pages report contains:

* Macro Analysis

* Report Card of MP Advisors Recommendation of 2012

* Top Picks for 2013

* Select Drug Approval in 2011-12 and Drug Launches in 2013-14

* Select Mid To Late Stage Drug Disappointments

* Cash Balance of Select Rs. Companies

* Challenges and Unmet Need of Innovators - Launched and Pipeline Unpartnered Compounds

* Resisting resistance - Emergence of Bad Bugs - GAIN Act

* New Targets And Drugs For Bad Bugs

* Select Mid To Late Stage Anti-Infective Pipeline For Serious Hospital Infections

* Retrograde Evolution- Where Innovation is Killed by Innovators

* Oral vs. Injectables - Select Oral RA Drugs in Development.

* In-depth Company Analysis and Reports on

* Top Picks

* Cempra - GAIN from Drugs for Bad Bugs

* Galapagos - GLPG0634 Excels vs. all JAK Inhibitors for RA.

* Incyte - JAKAFI/ JAKAVI Approved for Myelofibrosis and Drugs in Pipeline -Drivers of Growth

* Morphosys - Maturing Pipeline and Partnering/Acquisition in the Offing

* Outperforms

* ArQule - Failure in NSCLC - Disappointing but Not The End for Tivantinib

* Basilea - Ceftobiprole + Early Stage Pipeline Remains A Free Option!

* Medivir - Simeprevir in the HCV Race - Value Un-Appreciated!

* Rigel - Be in SyK (for RA)- Positives Coming Ahead

* SymBio - Novel Oncology Drug Portfolio Available as a Free Call Option!

* Trius - Partnering or Buy Out on the Cards.

* Vivus - Marketing Anti-obesity Drugs -Where Being First Has not Helped

* Market Performs

* Amarin - VASCEPA - Left to Fend on its Own!

* Aveo - Tivozanib - Wait May be Longer!

* Halozyme - rHuPH20 Benefits for Chronic Use - Still Under Scrutiny

* Immunomedics - Lack of Catalysts in Near Term

* ISIS - What More is Left Beyond KYNAMRO?

* Industry Tables

* Drug Clinical Milestones

* Drug Launch Table- 2013

* NPV Valuation

To order this report:

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

RELATED VIDEO:

Wednesday, 16 April 2014

Global Thermal Treatment Air Filtration Market 2012-2016

TechNavio's analysts forecast the Global Thermal Treatment Air Filtration market to grow at a CAGR of 7.55 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand from the process industries. The Global Thermal Treatment Air Filtration market has also been witnessing the increasing demand for end-to-end service. However, the increasing price wars among vendors could pose a challenge to the growth of this market.

TechNavio's report, Global Thermal Treatment Air Filtration Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Thermal Treatment Air Filtration market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Eisenmann AG, Durr AG, Megtec Systems Inc., Johnson Matthey plc, BASF SE, and Met pro Corp.

Other vendors mentioned in the report are Adwest Technologies Inc., Anguil Environmental, and Koch Industries Inc.

Key questions answered in this report:

* What will the market size be in 2016 and what will the growth rate be?

* What are the key market trends?

* What is driving this market?

* What are the challenges to market growth?

* Who are the key vendors in this market space?

* What are the market opportunities and threats faced by the key vendors?

* What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

To order this report:

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

RELATED VIDEO:

Internal Combustion Engine Filters - Global Markets Package

This market research report package offers a perspective on the actual market situation, trends and future outlook for internal combustion engine filters in different countries around the world. The studies provide essential market information for decision-makers including:

* Overall market for internal combustion engine filters in different countries

* Market for internal combustion engine filter by product type

* Forecasts and future outlook of the market

* Macroeconomic indicators

These market studies answer to questions such as:

* What is the size of the internal combustion engine filter markets in different countries around the world?

* How are the markets divided into different types of products?

* Which products are growing fast?

* How the markets have been developing?

* How does the future look like?

* What is the potential for the markets?

* How the macroeconomic indicators look like?

Product types discussed in the studies:

* Intake air filters

* Oil and petrol filters

Countries included in the package:

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Macedonia, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Armenia, Azerbaijan, China, Georgia, India, Indonesia, Iran, Japan, Jordan, Kazakhstan, Kyrgyzstan, Lebanon, Malaysia, Mongolia, Nepal, Oman, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Vietnam, Australia, Argentina, Bolivia, Canada, Chile, Colombia, Ecuador, Mexico, Panama, Peru, United States, Egypt, Ethiopia, Morocco, South Africa and sudan.

To order this report:

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600